Key Points
- CEO Daniel Barber sold 25,000 Aquestive Therapeutics shares at an average price of $4.82, generating $120,500. The Rule 10b5-1 transaction reduced his holdings by 3.69%, leaving him with 652,317 shares.
- AQST shares opened at $4.82 and have traded between $2.93 and $7.55 over the past year. The company’s latest quarterly loss of $0.18 per share missed estimates, though revenue of $13.82 million exceeded expectations.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $9.17, despite one sell rating. Institutional investors own 32.45% of the company.
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) CEO Daniel Barber sold 25,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $4.82, for a total transaction of $120,500.00. Following the transaction, the chief executive officer owned 652,317 shares in the company, valued at approximately $3,144,167.94. The trade was a 3.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Aquestive Therapeutics Trading Up 0.2%
Shares of AQST stock opened at $4.82 on Thursday. The stock has a market cap of $604.96 million, a P/E ratio of -7.42 and a beta of 1.48. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $7.55. The stock has a 50 day simple moving average of $4.42 and a 200 day simple moving average of $4.27.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to analysts' expectations of $11.42 million. Analysts forecast that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current year.
Hedge Funds Weigh In On Aquestive Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd bought a new stake in shares of Aquestive Therapeutics during the second quarter worth $210,000. Engineers Gate Manager LP raised its position in Aquestive Therapeutics by 20.5% in the second quarter. Engineers Gate Manager LP now owns 49,879 shares of the company's stock valued at $207,000 after purchasing an additional 8,496 shares during the last quarter. Wedbush Securities Inc. acquired a new stake in shares of Aquestive Therapeutics during the second quarter valued at about $60,000. Wellington Management Group LLP increased its stake in shares of Aquestive Therapeutics by 4.0% in the second quarter. Wellington Management Group LLP now owns 301,647 shares of the company's stock valued at $1,255,000 after buying an additional 11,587 shares during the period. Finally, Beacon Pointe Advisors LLC bought a new position in Aquestive Therapeutics in the 2nd quarter valued at approximately $252,000. Institutional investors own 32.45% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 24th. Cantor Fitzgerald reiterated an "overweight" rating and set a $11.00 price target on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $9.17.
Check Out Our Latest Stock Report on Aquestive Therapeutics
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company's dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.
Aquestive's commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
